Core Viewpoint - Zhonghe Particle Medical Technology Co., Ltd. has completed its first round of over 100 million yuan equity financing, led by Zhonghe Industrial Fund Management Co., Ltd. This funding will primarily support the R&D breakthroughs, engineering advancement, registration, clinical trial layout, and market demonstration of the company's three major product lines, laying a solid foundation for future product launches [1][4]. Company Introduction - Zhonghe Particle was established in 2019 and is headquartered in Beijing. It is a self-research platform for nuclear medical equipment under the China National Nuclear Corporation. The company focuses on the value concepts of "responsibility, safety, innovation, and collaboration," aiming to become a leader in international nuclear medical equipment development [4]. Product Introduction - Zhonghe Particle's three product lines cover core aspects of nuclear medical equipment: BNCT treatment equipment, nuclear medicine imaging equipment (SPECT), and medical electron linear accelerators. All three products are currently in critical R&D and demonstration application stages, establishing a foundation for future registration, production, and large-scale implementation [5]. BNCT Equipment - Boron Neutron Capture Therapy (BNCT) is a cutting-edge radiotherapy technology aimed at difficult-to-treat tumors. It has gained global attention due to its precise energy focusing and strong adaptability to complex tumor structures. In 2024, Zhonghe Particle successfully won the bid for the BNCT equipment project at Shandong Cancer Hospital, marking the transition from R&D prototypes to deployment in demonstration hospitals [6][8]. SPECT Equipment - Zhonghe Particle's SPECT imaging device is set to receive its medical device registration certificate from the National Medical Products Administration (NMPA) in 2025, becoming the company's first officially approved high-end medical equipment product. This device features innovative SPECT/3D optical fusion imaging technology, which enhances imaging accuracy and reduces errors caused by patient positioning [9][11][12]. Medical Electron Linear Accelerator - The company is advancing the development of its medical electron linear accelerator, which integrates diagnostic CT and accelerator technologies. This design improves treatment precision and reduces patient treatment burden, aligning with global trends towards high-precision and efficient radiotherapy equipment. Collaborations with major hospitals are underway to validate the product across various clinical scenarios [13]. Conclusion - The completion of Zhonghe Particle's first round of financing represents a significant milestone in the self-sufficiency of China's nuclear medical equipment sector. The three business lines—BNCT, SPECT, and linear accelerators—cover critical areas in advanced radiotherapy, nuclear medicine diagnosis, and precision radiotherapy, reflecting the ongoing accumulation of capabilities in R&D, manufacturing processes, and hospital validation systems [14].

Core Insights - The article highlights the advancements in proton therapy technology by China General Nuclear Power Group (CGN) and its subsidiary, CGN Medical Technology, which has established the first commercial multi-room proton therapy system production base in China [1] - The 230 MeV cyclotron, a key component of the proton therapy system, has been successfully produced, with three units completed in the first year of operation [1] - The company aims to achieve a world-class nuclear medical industry by 2030, leveraging local research and manufacturing capabilities in Mianyang, Sichuan [1] Company Overview - CGN Medical Technology has adopted a strategy of "introduction, digestion, absorption, and re-innovation" to develop its proton therapy systems, following successful practices in China's nuclear power sector [1] - The proton therapy system consists of 227 main devices and approximately 155,000 components, showcasing its complexity and technological sophistication [1] - The company has formed partnerships with over 80 upstream and downstream enterprises in the industry, promoting continuous technological innovation [1] Industry Context - The Sichuan province has implemented supportive policies to foster the development of the nuclear medical industry, aiming to establish itself as a global leader in medical isotope production and nuclear medical equipment manufacturing by 2030 [1] - The region's strong research and manufacturing foundation, exemplified by institutions like the China Engineering Physics Research Institute, contributes to the rapid growth of the nuclear medical sector in Mianyang [1] - The article emphasizes the potential for China to export its advanced imaging and treatment technologies internationally, marking a significant step in the global nuclear medical landscape [1]